The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC CLL 2026 | Choosing between fixed-duration and continuous BTK inhibitor therapy in newly diagnosed CLL
Marta Coscia, MD, PhD, University of Insubria, Varese, Italy, discusses the factors guiding her choice between a fixed-duration regimen and a continuous BTK inhibitor for patients with newly diagnosed chronic lymphocytic leukemia (CLL) who need therapy, including disease biology, patient characteristics, and logistics. Prof. Coscia highlights the importance of considering TP53 alteration status, immunoglobulin mutational status, infection risk, comorbidities, and patient preferences when making treatment decisions. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
